Society: SSAT

Background
Management of patients with margin negative, T1-T3, N0 (stage IB–IIIA), resected gallbladder cancer (GBC) remains poorly defined. Current guidelines consider observation, chemotherapy (CT), and chemoradiation (CRT) as options. The current study investigates the impact of CT/CRT on overall survival (OS) in these patients.

Methods
Patients with R0 resected stage IB–IIIA GBC were identified within the National Cancer Database. Relevant patient, tumor, and treatment data were analyzed. Multiple logistic regressions were performed for factors associated with receipt of hepatectomy and CT/CRT. Kaplan-Meier analysis for OS was performed. Logrank tests compared OS between treatment groups. Stage-by-stage multivariable Cox regressions assessed the impact of CT and CRT on mortality while adjusting for other risk factors.

Results
Of 2,070 patients identified, resection included cholecystectomy in 950 (45.9%) and cholecystectomy+hepatectomy in 1,120 (54.1%). Overall, 1,419 had resection alone (68.6%), 313 had resection+CT (15.1%), and 338 had resection+CRT (16.3%). Hepatectomy was more commonly performed at academic facilities (OR 2.538; CI 1.969-3.281; P<.01) and for stage IIIA disease (OR 2.670; CI 1.913-3.742; P<.01). Hepatectomy was associated with improved OS in stage IB-IIIA disease (logrank P<.01). Receipt of CT or CRT was associated with stage IIA-IIIA disease, hepatectomy, and private insurance (all P<.05). In univariable analysis, both CT (logrank P<.05) and CRT (logrank P<.01) were associated with improved OS only in patients with stage IIA-IIB disease who did not undergo hepatectomy. Within a multivariable Cox regression model adjusting for age, gender, comorbidities, insurance status, facility type, and tumor grade, only CRT was associated with decreased mortality for patients with stage IIA-IIB disease who did not undergo hepatectomy (HR 0.609; CI 0.400-0.888; P<.05).

Conclusions
The current national study demonstrates the importance of adequate surgical therapy for patients with potentially curable GBC. Among these patients, CT and CRT were not associated with improved OS. However, CRT did result in an OS benefit in patients who did not undergo optimal resection. Prospective trials focused on CT/CRT for adequately resected, node negative GBC are needed.

Introduction: The robotic platform is gaining a wider adoption in minimally invasive liver surgery, especially for complex resections. Difficulty scoring systems are a useful tool to predict the technical difficulty of each hepatectomy and to guide surgeons during operative planning. To date, difficulty scoring systems are available for laparoscopic but not for robotic hepatectomy. Because the robotic platform has unique technical characteristics when compared to the laparoscopic method in liver surgery, there is a need to design a difficulty scoring system specifically for robotic hepatectomy which we propose herein.
Methods: 328 consecutive patients undergoing robotic hepatectomy from a single institution were utilized to develop a difficulty scoring system. Patients requiring concomitant colorectal resection or undergoing planned conversion to ‘open’ hepatectomy were excluded. Operative duration and estimated blood loss (EBL) were utilized, among many markers, reflecting operative difficulty. Multivariate analysis was applied to determine the relationships between these markers of difficulty and relevant clinical factors.
Clinical factors utilized in the proposed robotic DSS were compiled after a comprehensive review of factors used by previously published IWATE, Institut Mutualiste Montsouris, and Southampton laparoscopic difficulty scoring systems, in addition to other relevant variables.
Every patient was given a corresponding robotic difficulty score and subsequently categorized into four groups based on their cumulative score (Group 1: 1-6, Group 2: 7-10, Group 3: 11-15, Group 4: 16-21). Patients’ perioperative outcomes between each group was compared. Data are presented as median(mean±SD). Significance was accepted at p≤0.05.
Results: Past surgical history, use of neoadjuvant chemotherapy, tumor location, tumor size, tumor type, proximity to major vessels, extent of parenchymal resection, need for portal lymphadenectomy, and need for biliary resection/reconstruction were significantly correlated with either operative time and/or EBL. Upon further analysis, 22 (7%) patients received a score of 1-6, 143 (44%) patients received a score of 7-10, 154 (47%) received a score of 11-15, and 9 (3%) patients received a score greater than 16. When stratified by difficulty score, there was a significant difference in patients’ Childs-Pugh score, rate of major resection, 30-day readmission, total cost, and fixed direct cost(p≤0.05).
Conclusions: Herein, we propose a novel difficulty scoring system (Table 1) for robotic hepatectomy utilizing clinical factors mentioned, which reflect technical difficulty. A further validation of this robotic difficulty scoring system is needed using larger multi-institutional collaborative datasets.

Introduction: Access to specialized oncologic care is critical for improved prognosis in pancreatic cancer. Studies have shown that patients living in high Area Deprivation Index (ADI) regions are more likely to have low median income, lack means of transportation and access to basic health care facilities. We aim to understand the impact of residing in areas of high ADI on access to care in patients with pancreatic cancer.

Methods: We performed a retrospective review of patients identified from an institutional database, from October 2017 to August 2022. Individual patient ADI ranks were assigned using a 9-digit zip code and divided into terciles, with high tercile indicating the most disadvantaged group. Chi-square test statistics are reported for factors impacted by ADI rank.

Results: 52.6% (n=105) of 223 patients resided in areas of medium to high deprivation. 50% of Black patients (n=24) lived in areas of high ADI compared with 10% of White patients (n=17). Residence in areas of higher ADI was significantly associated with decreased receipt of guideline concordant care (GCT) with 10% (n=14) of patients residing in high ADI areas receiving GCT, compared with 32.1% (n=45) of patients in medium ADI, and 57.9% (n=81) of patients in low ADI (χ2=18.69 p<0.001). Residence in areas of medium to high ADI were also associated with increased Emergency Department utilization (χ2=14.70 p=0.001), and with decreased prior cancer screening uptake (13.1% in high ADI compared with 29% in medium ADI and 57.9% in low ADI, χ2=8.08 p=0.018). There was no significant difference in access to primary care based on residence (χ2=4.21 p=0.122).

Conclusion: Patients with pancreatic cancer residing in areas of high ADI are less likely to receive evidence-based guideline-concordant care and are more likely to have higher ED utilization. Patients residing in high ADI areas are more likely to be Black and have lower cancer screening uptake, potentially indicating decreased access to healthcare. Further studies are needed to assess the impact of residence on delivery of GCT, as well as to assess specific barriers that may be addressed through targeted interventions.

Introduction
Treatment of pancreatic ductal adenocarcinoma (PDAC) can be challenging in the setting of liver cirrhosis. We sought to evaluate the effect of cirrhosis on surgical complications, time to recurrence (TTR), and overall survival (OS) following the resection of PDAC in cirrhotic patients.

Methods
This was a single-center retrospective analysis of patients who underwent curative-intent resection for PDAC. Patients with a preoperative diagnosis of cirrhosis were compared to non-cirrhotic patients. Propensity score matching (PSM) was performed using the AJCC 8^th edition TNM stage, preoperative serum level of CA 19-9, and surgical margin status. Postoperative complications, TTR, and OS were analyzed before and after PSM.

Results
We identified 1243 patients who fulfilled the inclusion criteria. Thirty-six patients (2%) had liver cirrhosis (80% Child-Pugh A, 17% Child-Pugh B, 3% Child-Pugh C) with an overall median MELD-Na of 11 (IQR 7.5-12.5) and were matched to 36 non-cirrhotic controls. After PSM, patients with cirrhosis had higher estimated blood loss (1000 ml, IQR 675-1600 vs. 650 ml, IQR 390-900, p=0.003), higher rates of major complications (42% vs. 12%, p=0.005), and a higher 30-day readmission rate (28% vs. 9%, p=0.042) than non-cirrhotic patients. No differences were found in TTR between both groups. However, median OS was substantially lower in patients with cirrhosis (14 months, 95% CI 11-20 vs. 33 months, 95% CI 20-not reached, p<0.001).

Conclusion
Patients with liver cirrhosis are at an increased risk of postoperative complications and associated with substantially worse survival following surgical resection of PDAC. Therefore, individualized risk-benefit assessment and multidisciplinary counseling are needed prior to consideration of pancreatectomy.

Time to recurrence and overall survival following resection of pancreatic ductal adenocarcinoma.

Time to recurrence and overall survival following resection of pancreatic ductal adenocarcinoma.

Postoperative complications before and after propensity score matching.

Postoperative complications before and after propensity score matching.

Background
The step-up approaches – percutaneous or endoscopic catheter drainage followed, if necessary, by minimally invasive surgical or endoscopic necrosectomy – are leading approaches for infected necrotizing pancreatitis after trials showed reduced morbidity compared to traditional open surgical necrosectomy. However, both the surgical and endoscopic step-up approaches are associated with the need for repeat interventions and prolonged hospitalization. The surgical transgastric approach to pancreatic necrosectomy (direct STGN) has been introduced for retrogastric collections to overcome these shortcomings. In this study, we aimed to describe outcomes for patients who have undergone direct STGN for infected necrosis.

Methods
This observational cohort study included patients who underwent direct STGN for infected pancreatic necrosis between 2011 and 2022 at two centers. Patients with sterile necrosis, a prior pancreatic intervention (i.e., interventional radiology drain, endoscopic transgastric drain) or a laparotomy after diagnosis of pancreatitis prior to STGN were excluded from analysis. Primary outcomes included mortality, length of hospital and intensive care unit (ICU) stay, new-onset organ failure, repeat interventions, readmissions and time to disease resolution (defined as the date of removal of the last percutaneous drain or date of discharge of initial admission or readmission).

Results
Forty-five patients underwent direct STGN for infected necrosis (21 open, 24 laparoscopic). The median age was 57 years (IQR 46–62) and 14 patients (31.1%) were female. On pre-operative imaging, 29 (64.4%) patients had more than 30% pancreatic necrosis. The median time to intervention from diagnosis of acute pancreatitis was 48 days (IQR 32–70). Pancreatitis-related mortality rate was 6.7% (n = 3). Following direct STGN, the median length of hospital stay was 8 days (IQR 6–17). ICU admission was required in 23 patients (51.1%) for a median of 1 day (IQR 0–3). New-onset organ failure occurred in 8 patients (17.8%). In 10 patients (22.2%), a surgical drain was left intraoperatively. Two patients (4.4%) required re-intervention (1 interventional radiology drain, duration 101d; 1 endoscopic transgastric drain). A pancreatic fistula was seen in one patient (2.2%). Eleven patients (24.4%) were readmitted. The median time to disease resolution was 6 days (IQR 6–22).

Conclusion
When anatomically possible, direct STGN offers an opportunity to treat patients with infected necrosis in a single procedure resulting in a short time to disease resolution. Due the low need for repeat interventions and few pancreatic fistulas, the direct STGN challenges the step-up approach for infected necrosis. Additional research is required to compare the different approaches.

Lymph node metastasis is a well-established negative predictor of survival in PDAC, however the independent predictive value of specific lymph nodes remains equivocal. In particular, the importance of a positive common hepatic artery lymph node (CHALN+) (station 8a) has been long debated. Earlier studies showed significantly impaired survival associated with CHALN+, but others have not. We sought to contribute to this debate utilizing a more contemporary cohort where the CHALN was prospectively identified.

We analyzed a cohort of patients with head of the pancreas PDAC who underwent pancreatoduodenectomy from 2010 to 2017. A single surgeon prospectively identified the CHALN intraoperatively and submitted it separately for permanent pathological analysis. Actual 5-year overall survival (OS) was available and calculated. Overall and disease-free survival (DFS) beyond 5 years was estimated per Kaplan Meier analysis and compared via log-rank test.

217 patients had excision of the CHALN in addition to other peripancreatic lymph nodes (PPLN). 75 (35%) were PPLN-/CHALN-, 125 (58%) were PPLN+/CHALN-, and 17 (7%) were PPLN+/CHALN+. No patients had CHALN+ in absence of PPLN+. Actual 5-year OS was 50% in PPLN-/HALN-, 14% in PPLN+/HALN-, and 20% in PPLN+/HALN+. Kaplan-Meier estimates of median OS showed a significant difference between PPLN-/CHALN- and PPLN+/CHALN- (47 vs 22 months; p<0.01) and between PPLN-/CHALN- and PPLN+/CHALN+ (47 vs 25 months; p=0.02) (Figure 1). However, there was no significant difference in OS between PPLN+/CHALN- and PPLN+/CHALN+ (p=0.8). Comparative values for DFS were 38, 13, and 9 months respectively, again with no significant difference between PPLN+/CHALN- and PPLN+/CHALN+.

This contemporary PDAC cohort with prospectively collected CHALN shows that when this lymph node is positive there is no difference in survival when compared to patients who have metastatic spread to other lymph nodes. Additionally, it shows an actual 5-year survival of 50% in patients who underwent pancreatoduodenectomy for PDAC and have negative lymph nodes, and 14-20% in patients with positive lymph nodes. This improvement from previously reported rates is likely a reflection of current adjuvant and neoadjuvant therapies.

Figure 1

Introduction:
Over the last decade a neoadjuvant-first approach has garnered increasing popularity in the management of pancreatic ductal adenocarcionma (PDAC). Systemic therapy is associated with considerable chemotoxocity, and chemotherapy intolerance is associated with performance status and comordibidities. Over a third of patients diagnosed with PDAC are aged ≥ 75 years. The aim of this study was to assess the utlization of neoadjuvant therapy (NAT) and its impact on survival in this cohort.
Methods:
The National Cancer Database (NCDB) was used to identify patients diagnosed with PDAC between 2010 and 2017 who underwent pancreatectomy. Patients were staged using the American Joint Committee on Cancer staging system. Patients with stage IV disease or those with missing data on stage or NAT were excluded. Demographic and clinicopathological characteristics were assessed using Chi Squared Test. Factors associated with receipt of NAT were identified using logistic regression. The association between NAT and hazard of mortality was assessed using Cox proportional hazards model. Median overall survival (OS) was examined.
Results:
A total of 26,346 patients were included of whom 21% were ≥75 years of age. Younger patients were more likely to have a Charlson-Deyo comorbidity score of 0 (64% vs. 60%, p<0.001). No significant differences were observed between the two cohorts in terms of tumor size, margin status, lymphovascular invasion and grade (all p-values>0.05).
NAT was administered in 12% of the elderly patients as compared to 24% in the younger cohort (p<0.001). After controlling for sex, race, tumor size, grade, clinical stage, and Charlson-Deyo comorbiditiy score, elderly patients were less likely to receive NAT (OR:0.46, 95%CI: 0.40-0.53, p<0.001). Charlson-Deyo score was not associated with receipt of NAT in the elderly cohort (p=0.986). On multivariate analysis, NAT was associated with improved survival in both the elderly (HR:0.80, 95%CI: 0.70-0.92, p=0.002) and younger cohort (HR:0.78, 95%CI: 0.73-0.83, p<0.001). In the younger cohort, median OS was 30.1 months for patients that received NAT and 23.2 months for those that did not (p<0.001) . In the elderly, median OS was 24.9 months for patients that received NAT and 17.8 months for those that did not (p<0.001).

Conclusion:
NAT is associated with improved OS in patients with PDAC who are ≥75 years of age compared to those that did not receive NAT. However, its utilization in this cohort remains significantly lower than in their younger counterparts. Comorbidities are not associated with the receipt of NAT in the older cohort. Furture studies are required to identify factors driving these lower rates which when addressed, could potentially help improve management in these patients.

Introduction:
Laparoscopic pancreaticoduodenectomy (LPD) has been shown to be safe, feasible, and potentially advantageous over open pancreaticoduodenectomy (OPD). However, there are reports of higher complications, namely postoperative pancreatic fistula (POPF), with LPD. We hypothesized that OPD was associate with lower complications and the aim of this study was to compare LPD to OPD regarding postoperative outcomes (Quality) as well as the financial burden (Cost) in order to obtain an overview of the Value (Quality/Cost) of LPD compared to OPD.
Methods:
From January 2010 to December 2020, OPD (n=347) and LPD (n=242) were performed by a surgical team using the same selection criteria, operative technique, and recovery protocols at a single institution. Total pancreatectomy, additional complex multivisceral resections, and major vascular reconstructions were excluded to diminish selection bias. Operative data and 90 day outcomes were compared and a statistical analysis was performed. Additionally, Cost required for surgery and recovery (additional OR time, readmissions and total hospital days, ICU days, postoperative imaging studies, radiologic and GI interventions, and need for TPN and blood transfusions) gathered and tabulated.
Results:
In all, 261 patients undergoing OPD were compared to 183 patients undergoing LPD. LPD patients were significantly younger (64.3 vs. 67.4, p=0.009) with higher BMI (28.4 vs. 26.7, p=0.002) but had similar rates of comorbidities, ASA, and ECOG status. LPD was associated with similar operative blood loss, transfusion rates, and need for vascular resection but had significantly longer operative times (472 vs 271 min, p=0.0001).
Regarding Quality of the operation, LPD was associated with similar mortality but significantly higher major complications, pancreatic fistula, hemorrhage, delayed gastric emptying, intra-abdominal abscess, need for postop imaging, need for intensive care, readmission, and total hospital stay (Table 1).
Regarding Cost, the mean Cost for LPD was significantly higher than for OPD (Table 1).
Conclusions:
According to this review at our institution, performing LPD appears to significantly worsen the Quality as well as increase the Cost of PD, therefore detracting significant Value from patients requiring PD. Additional unmeasured Costs including quality of life for the patient, unnecessary burden on the interventional and endoscopic support systems, and opportunity costs lost by the surgeon and OR team by the increase resources necessary for LPD should be examined and added to the overall Cost of LPD in future analyses.

Postoperative outcomes of 261 patients undergoing Open Pancreaticoduodenectomy (OPD) versue 183 patients undergoing Laparoscopic Pancreaticoduodenectomy (LPD) over a 10 year time period.

Postoperative outcomes of 261 patients undergoing Open Pancreaticoduodenectomy (OPD) versue 183 patients undergoing Laparoscopic Pancreaticoduodenectomy (LPD) over a 10 year time period.

Introduction:
Failure-to-rescue remains central to reducing mortality following pancreatic resection. Postoperative CT imaging has been shown to play an important role in intercepting failure-to-rescue precursors, though the timing of such imaging remains relatively understudied. We sought to examine the utility of immediate, early, and delayed pre-discharge abdominal CTs in pancreatectomy patients.

Methods:
Patients who underwent pancreatic resection at our institution from 2017-2022 were reviewed retrospectively. Clinical data and outcomes were recorded until 90 days postoperatively. Management before and after CT was analyzed for treatment changes and correlated with imaging findings. Patients were subdivided by the postoperative day that the first CT scan was obtained: immediate (POD<3), early (POD 3-7), and delayed (POD>7). Fisher exact/Chi-square, Student’s t, and rank sum tests were used with pairwise comparisons for the early and delayed groups.

Results:
Of 370 patients, 110 (30%) had a CT during the initial surgical stay. Indications included suspicion of infection in 60 (55%), bleeding in 10 (9%), and other concerns, such as severe pain or GI symptoms, in 40 (36%). A change in treatment was observed in 59% following CT, with 15% undergoing invasive interventions and 27% treated medically. Of those who had CT imaging, 12% had scans within 3 days (immediate), 54% days 3-7 (early), and 34% after day 7 (delayed). The three groups were similar in baseline characteristics such as age, comorbidities, pathology, operative time, and number of scans (table 1). Regarding imaging indications, concerns for bleeding (15%) were more common in the immediate period while infectious suspicions predominated the early (55%) and delayed (65%) groups. The proportion of patients undergoing pancreaticoduodenectomy increased with POD group (p=0.026). Comparing the early to the delayed group (table 2), antibiotic use and initiation day (80% vs 70%, POD 5.05 vs 6.15), percutaneous drainage and placement day (12% vs 14%, POD 12.9 vs 14.6), and overall invasive interventions during surgical stay (20% vs 30%) were all similar (p=NS). Both 30 and 90-day readmission rates were equivalent as well at 18% vs 15% and 32% vs 30%, respectively (p=NS). Importantly, those scanned in the early period had significantly shorter length of stay (17.05 vs 22.82, p=0.0008) and fewer composite days hospitalized (20.10 vs 24.93, p=0.0109) relative to the delayed group. Further, surgical stay mortality rates were significantly lower in the early versus delayed group (0% vs 11%, p=0.0191).

Conclusion:
In our cohort, patients imaged early after pancreatectomy experienced shorter hospital stays and lower inpatient mortality relative to those scanned after the first postoperative week. When intra-abdominal complications are suspected following pancreatectomy, axial imaging should not be delayed.

TABLE 1: Descriptive Data of Patients Undergoing CT After Pancreatectomy Grouped by Timing of First Postoperative Scan

TABLE 1: Descriptive Data of Patients Undergoing CT After Pancreatectomy Grouped by Timing of First Postoperative Scan

TABLE 2: Pairwise comparison of Interventions & Outcomes in the Early vs. Delayed CT Groups

TABLE 2: Pairwise comparison of Interventions & Outcomes in the Early vs. Delayed CT Groups

Aim: In this study, we aimed to elucidate the molecular mechanisms in the development of inflammatory pathways in chronic pancreatitis (CP); we compared the serum levels of inflammatory and oxidative stress markers in Chronic Pancreatitis (CP) patients and healthy controls and pro-inflammatory gene expression of tumor necrosis factor-alpha (TNF-α), Nuclear Factor kappa B (NFk-β), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2) were also compared with controls.
Method: This prospective study included participants with CP (n=45) between 18 -65 years. 45 healthy controls were also recruited. Serum biochemical and oxidative stress parameters viz, TAO, TOS, and MDA were measured. OSI index was calculated. Pancreatic tissues for gene expression study were collected from patients operated on for CP (n=25/45). Control tissues were obtained from patients who underwent surgery for carcinoma pancreas from the non-affected normal part of the pancreas (n=30). Real-time polymerase chain reaction (RT-PCR) was performed using extracted RNAs. Fold change was calculated relative to the controls using the 2-ddct formula.
Results: There were no significant differences in age and gender. Though the presenting symptom of all the patients was pain, none had a recent acute pain episode or elevated serum amylase levels. In our study group, none of the women were alcoholics. Leukocytosis and increased LFT were observed in cases. All oxidative stress parameters were significantly increased in patients compared to the control (Table 1). The median fold changes of TNF-α, NFk-β, and Cox-2 were significantly higher than controls (Table 2).
Conclusion: Our study observed the increased inflammatory process and oxidative stress in patients with CP compared with healthy controls. Upregulation of pro-inflammatory genes occurs in CP. Oxidative damage, usually associated with acute inflammation, is observed in patients with CP. All these findings of our study point to the fact that recurrent acute inflammation happens in patients with CP. This acute inflammation might be a significant contributor to the development and progression of the disease in patients with CP.

Introduction: High Emergency Department (ED) utilization increases the burden on healthcare expenditure. Pancreatic cancer patients are particularly susceptible to increased ED utilization due to disease-related deconditioning, cancer-related complications and treatment side-effects. In this study we aim to identify factors associated with ED utilization after diagnosis of pancreatic cancer.

Methods: We performed a retrospective chart review of patients with pancreatic cancer, using data from a single institution, from October 2017 to August 2022. Primary outcome was all cause ED visits. Univariate logistic regression and chi-square test values are reported for factors associated with ED visits.

Results: 235 patients with pancreatic cancer were identified, of whom 74 % (n=174) were White and 22.1% (n=52) were Black. 54% (n=128) were male, and 25.2% (n=59) had private insurance. Median age at diagnosis was 67.4 years (range 29-89 years). 100 patients (43%) had metastatic disease at initial presentation. 36.32% (n=85) had at least 1 ED visit after their initial diagnosis and 21%(n=50) returned multiple times. There were 200 ED visits overall, of which 138 resulted in inpatient admission. Mean length of stay after hospital readmission was 6.58 days (median 5 days, range:1-37 days). Race was significantly associated with return to ED (χ²=28.25 p<0.001), with Black or African American (63.5%) and multi-racial (80%) patients returning to ED more frequently than White patients (27.2%). Additionally, older age (χ²=17.73. p=0.007), residence in areas of high Area Deprivation Index (ADI) (χ²=14.70 p<0.001) and presence of ≥2 comorbidities (χ²=5.55 p=0.019) was associated with ED visits. Insurance status (p=0.744), gender (p=0.339) and disease stage at presentation (p=0.153) were not associated with return to ED in our patient population.

Conclusion: Sociodemographic variables are associated with increased ED utilization in pancreatic cancer care, and contribute to increased health care costs. Racial minority patients as well as patients residing in regions with high ADI are more likely to have increased ED utilization, indicating a lack of access to health care. Further studies are needed to assess intervention strategies to improve access and optimize delivery of care in patients with pancreatic cancer.

Background and Purpose
The critical view of safety (CVS) is an essential concept for safe emergent laparoscopic cholecystectomy (eLapC). In 2016, our institution proposed the preoperative "Onoe Score (OS)" to predict the ability to achieve CVS (Onoe S et al. HPB 2016). This scoring system includes three factors: CRP ≥5.5 mg/dL (2 points), gallstone impaction (1 point), and time duration from symptom onset to operation ≥72 hours (2 points). Since April 2021, we have used OS as a criteria for operator selection. Post-graduation year (PGY) 3–4 residents can perform only score 1 cases. If the score is 5, attending surgeons must perform the operation. We investigated the usefulness of OS in operator selection for eLapC.
Methods
Data from 571 patients who underwent eLapC for acute cholecystitis (AC) between January 2012 and October 2022 were collected retrospectively and divided into two groups: 436 patients before March 2021 (Before Onoe group: BO group) and 135 patients after April 2021 (After Onoe group: AO group). Clinical characteristics and surgical and postoperative outcomes were compared between groups. Propensity score matching was used to minimize selection bias. Patient propensity scores were calculated using all preoperative variables except the PGY of operators.
Results
Before matching (BO group vs. AO group), comparison of preoperative patient characteristics showed significant differences in age (64 vs. 70 years), anticoagulant therapy (8 vs. 20%), duration from onset to surgery (24 vs. 37 hours), ASA-PS≥3 (13 vs. 27%), CCI≥1 (34 vs. 56%). Preoperative blood tests showed significant differences in Cre (0.75 vs. 0.82), Alb (4.2 vs. 4.0) and PT-INR (1.04 vs. 1.06). Operator PGY distributions (PGY 3-4/5-9/10-) were 38%/53%/9% vs. 19%/71%/10%, respectively (p<0.001). In terms of surgical outcomes, there were significant differences in operative time (80 vs. 71 minutes), blood loss (10 vs. 20 ml), and CVS securement rate (80 vs. 70%). No significant differences were found in intraoperative injury rate (0.5 vs. 2.2%), open conversion rate (4.6 vs. 4.4%), and Clavien-Dindo≧3 postoperative complication rate (2.5 vs. 5.2%). After propensity score matching, 116 pairs were identified. Operator PGY distributions (PGY 3-4/5-9/10-) were 31%/57%/12% in the BO group vs. 20%/72%/8% in the AO group (p=0.049). Although blood loss, intraoperative injury rate, open conversion rate, and Clavien-Dindo≧3 postoperative complication rate did not significantly differ between groups, operative time (71 vs. 80 min: p=0.002) and postoperative hospital stay (3.3 vs. 3.9 days: p=0.003) were shorter in the AO group.
Conclusion
Utilizing OS for operator selection shortened operative time and hospital stay. Further data is needed to investigate the impacts on open conversion, intraoperative injuries, and postoperative complications.

Background: Pancreatoduodenectomy (PD) is the most challenging abdominal surgery requiring elaborate and strenuous procedures. Although laparoscopic PD could not become a standard due to high morbidity, the popularity of robotic PD has recently increased due to many advantages. we investigated current trends of types of PD focusing on the clinical role of robotic surgery.

Methods: Between 2015 and 2022, a total of 1658 PD was performed. 1120 patents underwent open PD, and 538 underwent robotic PD. Demographics and surgical outcomes were analyzed according to time period (first and late period), and propensity score-matched (PSM) analysis was performed to evaluate complications and clinical outcomes.

Results: The proportion of the robotic surgery was increased from 16.0% to 47.1% in the late period. Operation time was longer in the robot group (310.0 vs. 285.0 min, P < 0.001); however, estimated blood loss did not significantly differ (350.0 vs. 400.0 mL, P = 0.190). Complications of C-D grade 3a or higher (21.2% vs. 19.0%, P = 0.298) and CR-POPF rates (10.0% vs. 9.3%, P =0.626) were similar. Hospital stay was shorter in robot PD (8.0 days) than open PD (11.0 days). After PSM analysis, no significant difference of morbidity and there was no statistically significant difference in survival outcome between the two methods (Figure 1,2).

Conclusion: The number of robot PD has markedly increased in a relative short time showing comparable morbidity/mortality and oncologic outcome. Considering better recovery and cosmetic outcome, robot PD has become one of standard surgical method in pancreatic surgery.

figure1 overall survival of malignancy after PSM

figure1 overall survival of malignancy after PSM

figure2 overall survival of pancreatic cancer after PSM

figure2 overall survival of pancreatic cancer after PSM

Background: Our group has a long-standing interest in biliary infections. We have characterized factors facilitating development of severe biliary infections, including advanced age, bacterial slime, bacterial cholangiovenous reflux and induction of TNFα production (most common with E. coli and Klebsiella spp.). Recognized signs of cholangitis include fever/chills, jaundice, RUQ pain, hypotension, and altered mental status. We noted several cases with findings of new onset fatigue or weakness (separate from altered mental status) associated with severe biliary infections. We, therefore, studied the association between new onset fatigue or weakness (FatigWeak) and severity of the biliary infection.

Methods: We studied 1090 VA patients with gallstone disease [967 (89%) men, average age 64 years]. Gallstones, bile, and blood (as applicable) were cultured. Severity of illness was classified: None (no infectious/ inflammatory manifestations), Systemic Inflammatory Response Syndrome (SIRS - fever, leukocytosis, tachycardia), Severe (abscess, cholangitis, empyema), or Sepsis-Multiple Organ Dysfunction Syndrome (MODS - bacteremia, hypotension, organ failure). New onset fatigue or weakness (FatigWeak) was identified and correlated with clinical findings.

Results: Biliary bacteria were present in 52%, bacteremia in 117/456 (26%) cases. FatigWeak was present in 122 cases; these patients were older (74 vs 62 years, p<0.001), harbored biliary bacteria, and more often had bacteremia (48% vs 19%, p< 0.001) (Fig 1). Cases with FatigWeak more often had cultures positive for E. coli or Klebsiella species (60% vs 42%, p<0.001). New onset FatigWeak was associated with increased illness severity (Sepsis-MODS: 81% vs 15%, p<0.001) (Fig 2). In 23% of FatigWeak cases, onset proceeded development of sepsis (days to months). Additionally, 20% of patients with FatigWeak symptoms had associated weight loss. Presentations varied: some patients underwent medical evaluation of weakness before identification (or manifestation) of their biliary infection; others called 911 when weakness progressed to near paralysis. In these patients, FatigWeak symptoms resolved following treatment of the biliary infection. We also reviewed Reynold’s 1959 paper and noted that 1 of 6 cases he reported had weakness that preceded mental confusion and shock.

Conclusions: This study illustrates the important correlation between new onset fatigue or weakness and severe biliary infection, including biliary sepsis-MODS. FatigWeak was more common in cases with bacteremia, especially in those with E. coli and Klebsiella species. New onset FatigWeak could herald the development of biliary sepsis, emphasizing the need to consider biliary infection in these cases. This is the first paper to clearly show that FatigWeak is an important clinical indicator that can signify progression to cholangitis and MODS.

Background:
Bile peritonitis due to bile leak after T-tube removal in liver transplant recipients is frequently managed with urgent endoscopic retrograde cholangiopancreatography (ERCP). ERCP with stenting across the biliary anastomosis is an effective treatment to halt leakage and redirect bile flow, though there is no consensus on optimal stent type. At our institution, latex T-tubes (LT) were used in most patients with a duct-to-duct anastomosis. However, a supply shortage led to use of silastic T-tubes (ST) for approximately 4 months. Biliary outcomes with silastic T-tubes have not previously been described. We aim to describe our institution’s endoscopic approach to treating patients with bile leak after removal of ST compared to LT.

Methods:
A retrospective cohort study was performed evaluating patients who underwent liver transplantation with T-tube placement between 08/2021 and 04/2022. All reconstructions were performed using a continuous running technique with the T-tube brought out via a separate incision below the anastomosis in the common bile duct. The primary outcome was rate of bile leak in patients with LT compared to ST. Secondary outcomes included timing of ERCP, type of stent used and management at follow up ERCP. Fisher’s exact test was used to determine differences in bile leak management between LT and ST. Predictors of bile leak were assessed with unadjusted and adjusted logistic regression models.

Results:
19 LT patients and 23 ST patients were evaluated (Table 1). 75% of the first 4 ST patients had bile leaks after T-tube removal compared to 15.8% of 19 LT patients in the preceding 4 months. Based on this finding, 17 of the remaining ST patients underwent ERCP with prophylactic stenting and simultaneous T-tube removal. 47.8% of all ST patients had a bile leak clinically or during ERCP with cholangiogram, compared to 15.8% of all LT patients (p=0.03). After adjusting for age and gender using logistic regression, ST use was an independent predictor of bile leak (OR: 5.43, 95% CI 1.19-24.87, p=0.03).

There was no difference in type of stent placed at index ERCP (p=0.85) or in persistence of bile leak after stent placement (p=0.99) between patients with ST compared to LT. There was no difference in frequency of plastic versus metal stent among patients with ST, although 2 patients had symptomatic persistent bile leak after stenting with plastic stents (on day 2 and 3 following ERCP). The plastic stents were exchanged for metal in both cases leading to resolution of the leak.

Conclusions:
Almost half of liver transplant recipients with ST develop bile leak with T-tube removal, far exceeding the leak rate with LT. For patients with ST we recommend prophylactic ERCP with stenting and simultaneous T-tube removal to prevent bile peritonitis. We have a preference for fully covered metal stent placement if technically feasible.

Alexander Schlachterman

Appearances